Allergan PLC Company Profile (NYSE:AGN)

About Allergan PLC

Allergan PLC logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: AGN
  • CUSIP: 01849010
Key Metrics:
  • Previous Close: $230.80
  • 50 Day Moving Average: $242.98
  • 200 Day Moving Average: $241.15
  • 52-Week Range: $195.50 - $322.68
  • Trailing P/E Ratio: 22.00
  • Foreward P/E Ratio: 13.51
  • P/E Growth: 1.22
  • Market Cap: $91.48B
  • Outstanding Shares: 395,952,000
  • Beta: 0.73
  • Net Margins: 28.06%
  • Return on Equity: 7.67%
  • Return on Assets: 4.04%
  • Debt-to-Equity Ratio: 0.52%
  • Current Ratio: 0.99%
  • Quick Ratio: 0.91%
Additional Links:
Companies Related to Allergan PLC:

Analyst Ratings

Consensus Ratings for Allergan PLC (NYSE:AGN) (?)
Ratings Breakdown: 5 Hold Ratings, 17 Buy Ratings
Consensus Rating:Buy (Score: 2.77)
Consensus Price Target: $302.78 (31.47% upside)

Analysts' Ratings History for Allergan PLC (NYSE:AGN)
DateFirmActionRatingPrice TargetDetails
9/27/2016Goldman Sachs Group Inc.Reiterated RatingBuy$300.00View Rating Details
9/20/2016Bank of America Corp.Set Price TargetBuy$294.00View Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> HoldView Rating Details
9/14/2016MizuhoReiterated RatingBuy$305.00View Rating Details
8/30/2016Piper Jaffray Cos.Reiterated RatingNeutral$227.00View Rating Details
8/10/2016RBC Capital MarketsReiterated RatingOutperform$307.00 -> $300.00View Rating Details
8/8/2016Leerink SwannSet Price TargetBuy$294.00View Rating Details
8/9/2016Deutsche Bank AGLower Price TargetBuy$282.00 -> $278.00View Rating Details
8/9/2016Royal Bank Of CanadaLower Price TargetOutperform$307.00 -> $300.00View Rating Details
8/5/2016JPMorgan Chase & Co.Set Price TargetBuy$325.00View Rating Details
8/3/2016Credit Suisse Group AGSet Price TargetHold$322.00View Rating Details
6/29/2016Morgan StanleyReiterated RatingOverweightView Rating Details
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
6/9/2016Sanford C. BernsteinReiterated RatingOutperform$335.00View Rating Details
5/29/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
4/7/2016Raymond James Financial Inc.Lower Price TargetOutperform$317.00 -> $275.00View Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyView Rating Details
4/7/2016SusquehannaDowngradePositive -> Neutral$345.00 -> $275.00View Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00View Rating Details
7/29/2015Barclays PLCReiterated RatingHoldView Rating Details
6/20/2015BMO Capital MarketsSet Price TargetBuy$378.00View Rating Details
1/8/2015BTIG ResearchDowngradeBuy -> NeutralView Rating Details
12/15/2014Stifel NicolausDowngradeBuy -> Hold$200.00View Rating Details
11/18/2014Jefferies GroupReiterated RatingHold$184.00 -> $219.00View Rating Details
11/18/2014SunTrust Banks Inc.DowngradeBuy -> NeutralView Rating Details
11/18/2014William BlairDowngradeOutperform -> Market Perform$219.00View Rating Details
(Data available from 9/30/2014 forward)


Earnings History for Allergan PLC (NYSE:AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.18$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.38$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
2/4/2015Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
10/27/2014Q314$1.68$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
5/7/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan PLC (NYSE:AGN)
Current Year EPS Consensus Estimate: $14.00 EPS
Next Year EPS Consensus Estimate: $17.05 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$2.91$3.17$3.04
Q2 20161$3.29$3.29$3.29
Q3 20161$3.57$3.57$3.57
Q4 20161$4.14$4.14$4.14
(Data provided by Zacks Investment Research)


Current Dividend Information for Allergan PLC (NYSE:AGN)
Annual Dividend:$0.00
Dividend Yield:0.00%
Dividend Growth:-37.00% (3 Year Average)
Payout Ratio:0.00% (Based on Trailing 12 Months of Earnings)
0.00% (Based on Current Year Consensus EPS Estimate)
0.00% (Based on Next Year Consensus EPS Estimate)

Dividend History for Allergan PLC (NYSE:AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Allergan PLC (NYSE:AGN)
Insider Ownership Percentage: 0.27%
Institutional Ownership Percentage: 85.19%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Allergan PLC (NYSE:AGN)
DateHeadline logoAllergan plc Ordinary Shares Namenda Concerns Considered Insignificant - Evercore ISI - TCC (NYSE:AGN) - September 30 at 3:51 PM
News IconTraders Recap: SS&C Technologies Holdings, Inc. (NASDAQ:SSNC), Allergan plc. (NYSE:AGN) - Newburgh Press (NYSE:AGN) - September 30 at 3:51 PM logoCempra Gets More Good News (NYSE:AGN) - September 30 at 3:51 PM logoBiotech stocks have plenty of catalysts around the corner (NYSE:AGN) - September 30 at 8:29 AM logoTeva Has a Targeted Strategy to Expand in Major Growth Markets (NYSE:AGN) - September 30 at 8:29 AM logoAllergan (AGN) Comments on Namenda XR Patent Litigation; Will Depend Appeals Court Case - (NYSE:AGN) - September 29 at 3:34 PM logoBenzinga's M&A Chatter for Wednesday September 28, 2016 (NYSE:AGN) - September 28 at 10:12 PM
News IconAllergan to Present New Data at the American Urogynecologic Society Annual Meeting in Denver (NYSE:AGN) - September 27 at 3:21 PM
News IconTop Gainers of the Day: Allergan plc (NYSE:AGN) from Drugs – Generic (NYSE:AGN) - September 27 at 3:21 PM logoOrange County Business Council Study Showcases Economic Impact of Allergan on California Economy (NYSE:AGN) - September 27 at 3:21 PM
News IconAllergan plc (NYSE:AGN) from Drugs – Generic – Todays Top Gains (NYSE:AGN) - September 26 at 3:23 PM
News IconAllergan plc (NYSE:AGN) from Drugs – Generic – Todays Top Gains - Twin County News (NYSE:AGN) - September 26 at 9:33 AM logoDrugmaker Pfizer decides not to break up business (NYSE:AGN) - September 26 at 9:33 AM logoAllergan (AGN) Receives FDA Approval for NATRELLE INSPIRA Cohesive Breast Implants - (NYSE:AGN) - September 24 at 8:42 AM logo4:31 pm Allergan confirms FDA approval of Natrelle Inspira cohesive breast implants (NYSE:AGN) - September 24 at 8:42 AM logoAllergan Announces FDA Approval of NATRELLE INSPIRA® Cohesive Breast Implants (NYSE:AGN) - September 24 at 8:42 AM logoTwo Speculative NASH Allocations Post Allergan plc Ordinary Shares (NYSE:AGN)'s Tobira Therapeutics Inc ... - Market Exclusive (NYSE:AGN) - September 23 at 3:49 PM logoAllergan is Not Going to Buy Gilead - Bloomberg (NYSE:AGN) - September 23 at 8:11 AM
News IconHC Stocks News! Zoetis Inc (ZTS), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) (NYSE:AGN) - September 23 at 8:11 AM logoWill Allergan Buy Gilead? Don't Count On 'The Mother Of All Blockbusters' (NYSE:AGN) - September 22 at 3:49 PM
News IconMost Desiring Stocks- Mylan N.V. (NASDAQ:MYL), Allergan plc (NYSE:AGN) - Seneca Globe (NYSE:AGN) - September 22 at 3:21 PM logoNotable Thursday Option Activity: AGN, CBI, COTY (NYSE:AGN) - September 22 at 12:25 PM logoAllergan (AGN), Adamas Pharma (ADMP) Announces Availability of NAMZARIC, Donepezil Dosage Strengths - (NYSE:AGN) - September 22 at 9:16 AM
News IconHigh Profile Active Buzzers: Allergan plc (NYSE:AGN), Bristol-Myers Squibb (NYSE:BMY), TD Ameritrade (NASDAQ ... - Street Wise Report (press release) (blog) (NYSE:AGN) - September 21 at 4:18 PM
News IconAnalyst Buzz: Allergan plc. (NYSE:AGN), Exelon Corporation (NYSE:EXC) - Newburgh Press (NYSE:AGN) - September 21 at 4:18 PM
News IconSizzling Stock Alert - Allergan plc's (AGN) - Hot Stocks Point (NYSE:AGN) - September 21 at 4:18 PM logoAllergan pays $50 mln to buy privately-held Akarna Therapeutics - MarketWatch (NYSE:AGN) - September 21 at 10:22 AM logoAllergan to buy Tobira in deal valued at up to $1.7 billion - MarketWatch (NYSE:AGN) - September 21 at 10:22 AM logoAllergan plc Ordinary Shares: What Is AGN Getting for Its Billion Dollars? - (NYSE:AGN) - September 21 at 10:22 AM logoAllergan's Tobira Acquisition Represents The Highest Premium Ever Paid In Biopharma (NYSE:AGN) - September 21 at 8:00 AM logoGalmed Pharma shares jump on Allergan deal for maker of fatty liver disease drug (NYSE:AGN) - September 21 at 6:45 AM logoAllergan to buy Tobira in push for fatty liver disease drugs (NYSE:AGN) - September 21 at 5:27 AM logoAllergan to buy liver drug maker Tobira in deal potentially valued at $1.7B (NYSE:AGN) - September 20 at 5:57 PM logoAllergan buys second fatty liver-disease company (NYSE:AGN) - September 20 at 4:55 PM logoAllergan on a roll, buys another NASH therapy developer for $50M plus milestones (NYSE:AGN) - September 20 at 4:55 PM logoCowen Defends Allergan (NYSE:AGN) - September 20 at 4:36 PM logoAllergan's Preferred Shares, Series A Yield Pushes Past 6.5% (NYSE:AGN) - September 20 at 4:19 PM logoTobira Therapeutics, Inc. (TBRA) volatility low into Allergan plc (AGN) acquiring - (NYSE:AGN) - September 20 at 3:21 PM logoBiotech Buyout Fuels Unusual Options Activity on Allergan plc Ordinary Shares (AGN) - Schaeffers Research (blog) (NYSE:AGN) - September 20 at 3:21 PM logoAllergan is paying a stunning 500% premium to buy a clinical-stage biotech (NYSE:AGN) - September 20 at 2:52 PM logoAllergan pays top dollar for 'stepping stones' from neurology to dermatology (NYSE:AGN) - September 20 at 11:58 AM logoAllergan snares Bay Area drug maker for potential $1.7 billion (NYSE:AGN) - September 20 at 11:43 AM
News IconTobira Therapeutics Skyrockets on Allergan Acquisition (NYSE:AGN) - September 20 at 11:42 AM logoAllergan to buy Tobira in push for liver treatment, Tobira stock rises 600 percent (NYSE:AGN) - September 20 at 11:42 AM logoTobira Therapetuics Up 760% Following Allergan Buyout, Liver Drug A Key Focus (NYSE:AGN) - September 20 at 10:43 AM logoUPDATE 1-Allergan to buy Tobira in push for NASH treatments (NYSE:AGN) - September 20 at 9:45 AM logoAllergan to Acquire Tobira Therapeutics Expanding Global GI R&D Pipeline and Taking a Leading R&D Position in NASH (NYSE:AGN) - September 20 at 9:09 AM logoAllergan To Acquire Tobira For Potential Consideration Of Up To $1.695 Bln (NYSE:AGN) - September 20 at 9:09 AM logoAllergan to buy Tobira in deal valued at up to $1.7 billion (NYSE:AGN) - September 20 at 9:09 AM logoAllergan's Tobira takeover stokes NASH stocks (NYSE:AGN) - September 20 at 9:09 AM


Allergan PLC (NYSE:AGN) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff